Mia Hu

Nuevocor Pte Ltd. is a biotechnology company based in Singapore, Singapore. The Singaporean company pioneers an innovative pathway-centric approach to developing genetic medicines for heart conditions known as cardiomyopathies. Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases by harnessing their Prosia mechanobiology platform. The company's approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables them to extend their impact to broader patient populations. The company was founded by Colin Stewart, Mark Kay, Jianming Jiang, Yin Loon Lee, Tan Yann Chong, Brian Burke. Tan Yann Chong has been the CEO since incorporation.

Nuevocor Pte Ltd. is a biotechnology company based in Singapore, Singapore. The Singaporean company pioneers an innovative pathway-centric approach to developing genetic medicines for heart conditions known as cardiomyopathies. Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases by harnessing their Prosia mechanobiology platform. The company's approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables them to extend their impact to broader patient populations. The company was founded by Colin Stewart, Mark Kay, Jianming Jiang, Yin Loon Lee, Tan Yann Chong, Brian Burke. Tan Yann Chong has been the CEO since incorporation.

Nuevocor Pte Ltd. is a biotechnology company based in Singapore, Singapore. The Singaporean company pioneers an innovative pathway-centric approach to developing genetic medicines for heart conditions known as cardiomyopathies. Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases by harnessing their Prosia mechanobiology platform. The company's approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables them to extend their impact to broader patient populations. The company was founded by Colin Stewart, Mark Kay, Jianming Jiang, Yin Loon Lee, Tan Yann Chong, Brian Burke. Tan Yann Chong has been the CEO since incorporation.